SYNGENE - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.7
| Stock Code | SYNGENE | Market Cap | 17,756 Cr. | Current Price | 440 ₹ | High / Low | 729 ₹ |
| Stock P/E | 49.1 | Book Value | 117 ₹ | Dividend Yield | 0.28 % | ROCE | 10.0 % |
| ROE | 7.74 % | Face Value | 10.0 ₹ | DMA 50 | 450 ₹ | DMA 200 | 525 ₹ |
| Chg in FII Hold | -1.05 % | Chg in DII Hold | 0.61 % | PAT Qtr | 154 Cr. | PAT Prev Qtr | 68.7 Cr. |
| RSI | 45.1 | MACD | -0.70 | Volume | 6,68,009 | Avg Vol 1Wk | 6,05,861 |
| Low price | 380 ₹ | High price | 729 ₹ | PEG Ratio | -5.83 | Debt to equity | 0.04 |
| 52w Index | 17.3 % | Qtr Profit Var | -11.8 % | EPS | 7.57 ₹ | Industry PE | 39.7 |
📊 SYNGENE (Syngene International Ltd.) trades at a P/E of 49.1 compared to the industry average of 39.7, indicating premium valuations. ROCE (10.0%) and ROE (7.74%) are modest, while dividend yield of 0.28% offers minimal income support. EPS of ₹7.57 is stable, but PEG ratio (-5.83) highlights growth concerns. Debt-to-equity of 0.04 ensures strong balance sheet health. Current price ₹440 is near 50 DMA (₹450) and below 200 DMA (₹525), reflecting weakness.
💡 Entry Price Zone: Ideal entry lies between ₹410–₹440, with deeper accumulation possible around ₹380–₹400 if market correction persists.
📈 Exit Strategy / Holding Period: For existing holders, SYNGENE is a moderate long-term candidate. Hold for 2–4 years, targeting exits near ₹500–₹520 if valuations recover. Monitor ROCE improvement and earnings growth as key drivers. Consider trimming positions if profitability remains stagnant.
Positive ✅
- 📌 Low debt-to-equity ratio (0.04) ensures financial stability.
- 📌 EPS of ₹7.57 supports valuation base.
- 📌 Quarterly PAT growth (₹68.7 Cr → ₹154 Cr) shows operational improvement.
- 📌 RSI at 45.1 indicates neutral momentum.
Limitation ⚠️
- 📌 Weak ROCE (10.0%) and ROE (7.74%).
- 📌 Elevated P/E ratio of 49.1 compared to industry average (39.7).
- 📌 Negative PEG ratio (-5.83) highlights growth concerns.
- 📌 Sequential profit variation (-11.8%) indicates earnings volatility.
Company Negative News 📉
- 📌 Reduction in FII holdings (-1.05%).
- 📌 Stock trading well below 52-week high (₹729).
Company Positive News 📈
- 📌 Increase in DII holdings (+0.61%).
- 📌 Quarterly PAT improvement despite volatility.
Industry 🌐
- 📌 Industry P/E at 39.7 suggests sector is moderately valued.
- 📌 Biotech and pharma research sector benefits from rising global demand for contract research and development services.
Conclusion 🧬
SYNGENE is a moderate long-term candidate with strong balance sheet health but weak ROE and ROCE. Entry between ₹410–₹440 offers favorable risk-reward, with deeper value near ₹380–₹400. Hold for 2–4 years, with partial exits near ₹500–₹520. Long-term sustainability depends on improving profitability and maintaining growth momentum.
Would you like me to expand this into a peer benchmarking to compare Syngene against other biotech and pharma research leaders for valuation and efficiency?